A Bright Outlook for Companies—and Patients—in a Value-Based Health Care World

Renewed optimism and significant opportunities exist for biopharma companies. The most successful companies will have robust scientific, commercial, and operational capabilities to thrive in an increasingly value-based health care environment. Whether in specialty care, primary care, biotech, pharma, generics, or the consumer or over-the-counter segment, this is an exciting—and unprecedented—time for a global industry poised to deliver outcomes that create proven value for patients.

Externally sourced innovation and growth are critical to success. OGG's exclusive Biopharma Partnering Survey and Benchmarking analysis examines licensing and business development activity in the global biopharmaceutical industry.